• Vaccine Name: Menactra
• Target Pathogen: Neisseria meningitidis
• Target Disease: Meningitis
• Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
• Tradename: Menactra
• Manufacturer: Sanofi Pasteur Inc.
• Vaccine Ontology ID: VO_0000071
• CDC CVX code: 114
• Type: Conjugate vaccine
• Status: Licensed
• Location Licensed: USA (License #1725), Canada
• Host Species for Licensed Use: Human
• Allergen: Latex
• Preparation: Cultured on Mueller Hinton agar and grown in Watson Scherp media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration (FDA: Menactra).
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
• Approved Age for Licensed Use: 2-55 years of age.
• Contraindication: This vaccine should not be administered to anyone with known hypersensitivity to any component of Menactra vaccine including diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components (FDA: Menactra).
• Description: Contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. Menactra vaccine is not indicated for immunization against diphtheria (FDA: Menactra).

Human Response

• Immune Response: Clinical studies reported antibodies were seen in 90-100% of those who were vaccinated with Menactra (FDA: Menactra).
• Side Effects: Side effects of vaccination include: injection site reactions, headache, fatigue, irritability and fever.